Tailored to the specific needs of the German cannabis market.
Despite years of market growth, the German cannabis industry remains complex and opaque, lacking transparency on its supply chain and customer journey. Data crucial for analyzing key business aspects such as market shares, sales performance, price development, product availability, and product quality is either missing or prohibitively expensive.
We will change this.
All insights. All market players. Full transparency. One Platform.
Our hosted BI solution provides insights on product data, pricings, stock availabilites, market shares, and more. Fast, easy, powerful. Use our out-of-the-box dashboards or start tailoring dashboards to your needs.
We built the hard thing first: a universal data engine, tailored to specific market needs.
We give BI-teams and technical developers the extensible data to build their own proprietary solutions. Our data processing and mapping tools additionally help teams to put their data to work with ease.
Collecting data is easy. Connecting it and putting it to work is hard. We focs on heavy lifting of mass data and unifying data silos to unlock new insights.
That’s why we built the hard things first: a universal and constantly evolving cannabis product engine.
We operate own proprietary servers consolidating point-of-sale data and many others data-streams.
We cooperate with multiple data providers and partners to enrich our data with additional perspectives.
Our central intelligence layer applies state-of-the-art technology on all of these combined data sources.
Until our platform launches in early Q1/2025 we provide tailored reports and detailed analysis specifically tailored to your individual needs and questions.
Join our already existing customers and find out where we can help.
Explore the dynamics of Germany’s medical cannabis market with our free and regularly updated market overview report.
Track pricing and availability of 700+ products and dive into the competitive landscape of dry flowers in Germany.
Analyze pricing and availability of over 140 products, including the competitive landscape of medical cannabis extracts.
Who is participating in the race for the next cannabinoid-based registered drug? Who is approaching clinical trials with which focus?